Abstract
Patient-Reported Outcomes (PROs) capture patient’s subjective perception of the effects of a disease or treatments. Previous reports have indicated that regulators have different approaches in inclusion of PROs as endpoint measures in the drug approval process. We aim at highlighting such differences by investigating the current use of PROs, as endpoints in oncology trials and label claims granted by the FDA in comparison with the EMA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
